MedTrace Logo

Safety Study of an Oral Vaccine to Prevent Avian Influenza

NCT01335347 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2013-01-03

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the safety and immunogenicity of an oral vaccine to prevent avian influenza. Volunteers will receive either one or two doses of research vaccine or placebo as part of this study.

Conditions

Interventions

BIOLOGICAL

ND1.1

adenovirus with the dsRNA adjuvant, dried and put into capsules

BIOLOGICAL

Placebo control

Capsules of the same size and shape as experimental groups

Sponsors & Collaborators

  • Vaxart

    lead INDUSTRY

Principal Investigators

  • Sean N Tucker, PhD · Vaxart

  • Martin Kabongo, MD, PhD · Accelovance

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-08-31
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01335347 on ClinicalTrials.gov